View Older Stories View More Recent Stories

Jun 1, 2022 08:43AM Kymera Therapeutics (KYMR) Granted FDA Orphan Drug Designation for KT-333
Jun 1, 2022 08:42AM Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
Jun 1, 2022 07:00AM Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
May 20, 2022 07:30AM Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
May 5, 2022 08:00AM Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Infla
May 5, 2022 08:00AM Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Infla
Apr 19, 2022 08:00AM Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
Apr 19, 2022 08:00AM Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
Apr 8, 2022 01:05PM Kymera Therapeutics (KYMR) Presents Preclinical Data of MDM2 Degradation at AACR
Apr 8, 2022 01:02PM Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Ca
Apr 8, 2022 01:02PM Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Ca
Jan 25, 2022 08:00AM Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences
Jan 25, 2022 08:00AM Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences
Jan 18, 2022 08:03AM Kymera Therapeutics (KYMR) Appoints John Maraganore to its Board
Jan 18, 2022 08:00AM Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
Jan 18, 2022 08:00AM Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
Jan 10, 2022 07:00AM Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
Jan 10, 2022 07:00AM Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
Jan 4, 2022 08:00AM Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Jan 4, 2022 08:00AM Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Dec 16, 2021 07:03AM Kymera Therapeutics (KYMR) Reports New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision
Dec 16, 2021 07:00AM Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day
Dec 16, 2021 07:00AM Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D D
Dec 13, 2021 08:04AM Kymera Therapeutics (KYMR) Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at ASH
Dec 13, 2021 08:00AM Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Dec 13, 2021 08:00AM Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Dec 6, 2021 08:00AM Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
Dec 6, 2021 08:00AM Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
Nov 30, 2021 08:02AM Kymera Therapeutics (KYMR) Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Nov 30, 2021 08:00AM Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Nov 30, 2021 08:00AM Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Nov 17, 2021 08:00AM Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
Nov 17, 2021 08:00AM Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
Nov 12, 2021 07:00AM Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Nov 12, 2021 07:00AM Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Nov 10, 2021 07:00AM Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
Nov 10, 2021 07:00AM Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
Nov 4, 2021 08:00AM Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annua
Nov 4, 2021 08:00AM Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annua
Nov 1, 2021 08:00AM Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
Nov 1, 2021 08:00AM Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
Oct 27, 2021 07:00AM Kymera Therapeutics (KYMR) Reports Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-47
Oct 27, 2021 07:00AM Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Ph
Oct 27, 2021 07:00AM Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Ph
Oct 20, 2021 08:00AM Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th
Oct 20, 2021 08:00AM Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th
Oct 13, 2021 07:00AM Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Tar
Oct 13, 2021 07:00AM Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Tar
Sep 2, 2021 08:00AM Kymera Therapeutics to Present at Upcoming September Investor Conferences
Sep 2, 2021 08:00AM Kymera Therapeutics to Present at Upcoming September Investor Conferences
View More Recent Stories View Older Stories